Pulmonary Drug Delivery System for inhalation therapy in mechanically ventilated patients

Expert Review of Medical Devices

Volumn 5, Issue 1, 2008, Pages 9-18

  Dhand, Rajiv ^a   Sohal, Harjyot ^a  

^a University of Missouri   (United States)

Author keywords

Aerosol; Antibiotic vibrating mesh; Nebulizer; Ventilator associated pneumonia

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; BRONCHODILATING AGENT; CEFTAZIDIME; CORTICOSTEROID; ILOPROST; TOBRAMYCIN;

ARTICLE; ARTIFICIAL VENTILATION; BIOMEDICAL TECHNOLOGY ASSESSMENT; BREATHING PATTERN; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG DELIVERY SYSTEM; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SPUTUM LEVEL; DRY POWDER; HOSPITAL INFECTION; HUMAN; LUNG INFECTION; MEDICAL NEBULIZER; METERED DOSE INHALER; POSTMARKETING SURVEILLANCE; PULMONARY HYPERTENSION; SINGLE DRUG DOSE; UNSPECIFIED SIDE EFFECT; VENTILATOR ASSOCIATED PNEUMONIA;

AEROSOLS; DRUG DELIVERY SYSTEMS; HUMANS; NEBULIZERS AND VAPORIZERS; RESPIRATION, ARTIFICIAL; RESPIRATORY THERAPY;

EID: 38049107842     PISSN: 17434440     EISSN: 17452422     Source Type: Journal    
DOI: 10.1586/17434440.5.1.9     Document Type: Article

References (52)

1. Rau JL. Design principles of liquid nebulization devices currently in use. Respir. Care 47, 1257-1275 (2002).
2. Dalby RN, Tiano SL, Hickey AJ. Medical devices for the delivery of therapeutic aerosols to the lungs. In: Inhalation Aerosols: Physical and Biological Basis for Therapy Lung Biology in Health and Disease (Volume 94). Hickey AJ (Ed.). Marcel Dekker, NY, USA, 441-473 (1996).
3. Hess DR. Nebulizers: priniciples and performance. Respir Care 45(6), 609-622 (2000).
4. Niven RW. Atomization and nebulizers. In: Inhalation Aerosols: Physical and Biological Basis for Therapy. Hickey AJ (Ed.). Marcel Dekker, NY, USA 273-312 (1996).
5. O'Callaghan C, Barry PW. The science of nebulized drug delivery. Thorax 52(Suppl. 2), S31-S44 (1992).
6. Dhand R. Nebulizers that use a vibrating mesh or plate with multiple apertures to generate aerosol. Respir. Care 47, 1406-1416; discussion 1416-1418 (2002).
7. Dennis JH, Nerbrink O. New nebulizer technology. In: Drug Delivery to the Lung. Bisgaard H, O'Callaghan C, Smaldone GC (Eds). Marcel Dekker, NY, USA 303-336 (2002).
8. Mercier E, Valat A, Fishman RS et al. Aerosol delivery of amikacin by three nebulizers of varying efficiency in patients on mechanical ventilators. Am. J. Respir. Crit. Care Med. 169, A657 (2004).
9. Greenspan BJ. Ultrasonic and electrohydrodynamic methods for aerosol generation. In: Inhalation Aerosols: Physical and Biological Basis for Therapy Lung Biology in Health and Disease (Volume 94). Hickey AJ (Ed.). Marcel Dekker, NY, USA 313-335 (1996).
10. Alvine GF, Rodgers P Fitzsimmons KM, Ahrens RC. Disposable jet nebulizers. How reliable are they? Chest 101, 316-319 (1992).
11. Loffert DT, Ikle D, Nelson HS. A comparison of commercial jet nebulizers. Chest 106, 1788-1792 (1994).
12. Waldrep JC, Keyhani K Black M, Knight V. Operating characteristics of 18 different continuous-flow nebulizers with bedomethasone dipropionate liposomal aerosol. Chest 105, 106-110 (1994).
13. Hess D, Fisher D, Williams P, Pooler S, Kacmarek RM. Medication nebulizers performance: effects of diluent volume, nebulizers flow, and nebulizers brand. Chest 110, 498-505 (1996).
14. Mercer TT, Goddard RF, Flores RL. Output characteristics of three ultrasonic nebulizers. Ann. Allergy 26, 18-27 (1968).
15. Harvey CJ, O'Doherty MJ, Pagr CJ, Thomas SHL, Nunan TO, Treacher DF. Comparison of jet and ultrasonic nebulizer pulmonary aerosol deposition during mechanical ventilation. Eur. Respir. J. 10, 905-909 (1997).
16. Coates AL, MacNeish CF, Lands LC, Meisner D, Kelemen S, Vadas EB. A comparison of the availability of tobramycin for inhalation from vented vs unvented nebulizers. Chest 113, 951-956 (1998).
17. Dennis JH. Drug nebulizer design and performance: breath enhanced jet vs. constant output jet vs ultrasonic. J Aerosol Med. 8, 277-280 (1995).
18. Rau JI, Arzu, A, Restrepo RD. Performance comparison of nebulizer designs: constant-output, breath-enhanced, and dosimetric. Respir. Care 49, 174-179 (2004).
19. Dennis JH, Stenton SC, Beach JR, Avery AJ, Zalters EH, Hendrick DJ. Jet and ultrasonic nebulizer output: use of a new method for direct measurement of nebulizer output. Thorax 54, 728-732 (1990).
20. Niven RW, Ip AY, Mittelman S, Prestreliski SJ, Arakawa T. Some factors associated with the ultrasonic nebulization of proteins. Pharm. Res. 12, 53-59 (1995).
21. Thomas SHL, O'Doherty MJ, Page CJ, Treacher DF, Nunan TO. Delivery of ultrasonic nebulized aerosols to a lung model during mechanical ventilation. Am. Rev. Respir. Dis. 148, 872-877 (1993).
22. Steckel H, Eskandar F. Facors affecting aerosol performance during nebulization with jet and ultrasonic nebulizers. Eur. J. Pharm. Sci. 19, 443-455 (2003).
23. Phillips GD, Millard FJL. The therapeutic use of ultrasonic nebulizers in acute asthma. Respir. Med. 88, 387-389 (1994).
24. Nikander K, Turpeinen M, Wollmer P. The conventional ultrasonic nebulizer proved inefficient in nebulizing a suspension. J. Aerosol Med. 12, 47-53 (1999).
25. Smaldonec GC, Nikander K. Bench performance and in vivo deposition efficiency of the I-neb adaptive aerosol delivery system (AAD) during tidal versus slow and deep breathing. Proc. Aerosol Soc. DDL 15, 17-20 (2004).
26. Dhand R. Future directions in aerosol therapy. Respir. Care Un. N. Am. 7(2), 319-335 (2001).
27. Nikander K. Drug delivery systems. J. Aerosol Med. 7(Suppl. 1), S19-S24 (1994).
28. Dhand R. New frontiers in aerosol delivery during mechanical ventilation. Respir. Care. 49(6), 666-677 (2004).
29. Wagner A, Vorauer-Uhl K, Katinger H. Nebulization of liposomal rh-Cu/ Zn-SOD with a novel vibrating membrane nebulizer. J. Liposome Res. 16, 113-125 (2006).
30. Pedersen KM, Handlos VN, Heslet L, Kristensen HG. Factors influencing the in vitro deposition of tobramycin aerosol: a comparison of an ultrasonic nebulizer and a high-frequency vibrating mesh nebulizer. J. Aerosol Med. 19, 175-183 (2006).
31. Fink JB, MacLoughlin R. Impact of continuous and phasic aerosol generation on drug delivery during mechanical ventilation: an in vitro analysis. Poster presentation at: 68th American College of Chest Physicians Annual Conference. San Diego, CA, USA, 3-7 November 2002.
32. Lentz YK, Anchordoguy TJ, Lengsfeld CS. Rationale for the selection of an aerosol delivery system for gene delivery. J. Aerosol Med. 19, 372-384 (2006).
33. Nikander K. Adaptive aerosol delivery: the principles. Eur. Repir. Rev. 7, 385-387 (1997).
34. Denyer J. Adaptive aerosol delivery in practice. Eur. Respir. Rev. 7, 388-389 (1997).
35. Smaldone GC. Advances in aerosols: adult respiratory disease. J. Aerosol Med. A 36-46 (2006).
36. Ahrens RC, Ries RA, Popendorf W, Wiese JA. The delivery of therapeutic aerosols through endotracheal tubes. Pediatr. Pulmonol. 2, 19-26 (1986).
37. Newman SP. How well do in vitro particle size measurements predict drug delivery in vitro. J. Aerosol Med 11(1), S97-S103 (1998).
38. Dior P, Morra L, Smaldone GC. Albuterol delivery in a model of mechanical ventilation. Comparison of metered-dose inhaler and nebulizer efficiency. Am. J. Respir. Crit. Care Med. 152, 1391-1394 (1995).
39. Miller DD, Amin MM, Palmer LB, Shah AR, Smaldone GC. Aerosol delivery and modern mechanical ventilation: in vitro/in vivo evaluation. Am. J. Respir. Crit. Care Med. 168, 1205-1209 (2003).
40. Fink JB, Dunne P, O'Sullivan G. Can high efficiency aerosol delivery continue after extubation. Poster presented at: International Symposium on Intensive Care and Emergency Medicine. Brussels, Belgium, 21-25 March 2005.
41. Bressolle F, de la. Coussaye JE, Ayoub R et al. Endotracheal and aerosol administration of ceftazidime in patients with nosocomial pneumonia: pharmacokinetics and absolute bioavailability. Antimicrob. Agents Chemother. 36, 1404-1411 (1992.).
42. Ilowite JS, Gorvoy JD, Smaldone GC. Quantitative deposition of aerosolized gentamicin in cystic fibrosis. Am. Rev. Respir. Dis. 136(6), 1445-1449 (1987).
43. LeConte P, Potel G, Peltier P et al. Lung distribution and pharmacokinetics of aerosolized tobramycin. Am. Rev. Respir. Dis. 147, 1279-1282 (1993).
44. Goldstein I, Wallet F. Nicolas-Robin A et al. Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. Am. J. Respir. Crit. Care Med. 166, 1375-1381 (2002).
45. Geller DE, Pitflick WH, Nardella PA et al. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest 122, 219-226 (2002).
46. Touw DJ, Jacobs FA, Brimicombe RW et al. Pharmacokinetics of aerosolized tobramycin in adult patients with cystic fibrosis. Antimicrob. Agents Chemother. 41, 184-187 (1997).
47. Cooney GF. Lum BL, Tomaselli M, Fiel SB. Absolute bioavailability and absorption characteristics of acrosolized tobramycin in adults with cystic fibrosis. J. Clin. Pharmacol. 34, 255-259 (1994).
48. Niederman MS, Sanchez M, Corkery K, Guntupali K, Luyt CE, Chastre J. Amikacin aerosol achieves high tracheal aspirate concentrations in intubated mechanically ventilated patients with Gram-negative pneumonia. Am. J. Respir. Crit. Care Med 175, A327 (2007).
49. Chastre J, Sanchez M, Corkery K, Fink JB, Luyt CE, Niederman MS. Amikacin aerosol achieves safe serum concentrations after repeat dosing in intubated mechanically ventilated patients with Gram-negative pneumonia: a pharmacokinetic study. Am. J. Respir. Crit. Care Med. 175, A328 (2007).
50. Niederman MS, Chastre J, Corkery K et al. the Amikacin Study group. Inhaled amikacin reduces IV antibiotic use in intubated mechanically ventilated patients during treatment of Gram-negative pneumonia. Am. J. Respir. Crit. Care Med. 175, A327 (2007).
51. Dhand R. The role of aerosolized antimicrobials in the treatment of ventilator-associated pneumonia. Respir Care 52, 866-884 (2007).
52. Dhand R, Mercier E. Effective inhaled drug administration to mechanically ventilated patients. Expert Opin. Drug Deliv. 4, 47-61 (2007).